Behavioral Drivers of Oncologists' Treatment Practices
Emotional Influencers on Oncologists' Treatment Practices
A detailed study from OncCentral uncovers:
  • Non-clinical factors impacting treatment choice
  • Physician segments impacted by emotional factors

Biomarkers in Immuno-Oncology
Biomarkers in Immuno-Oncology:  Sorting through the Noise and Confusion
 • Uncover their relevance to your patient population and the available treatment options 
• Get a clear road map of biomarker applications and their use in diagnosis and treatment choice
 • Hear from key thought leaders to understand industry impact 

FDA Approves Niraparib for Ovarian CancerThe FDA has approved the PARP inhibitor niraparib (Zejula) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Read more
Nivolumab Recommended for EU Approval in Head and Neck CancerThe EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of nivolumab (Opdivo) for the treatment of patients with squamous cell cancer of the head and neck (SCCHN) following progression on platinum-based therapy, according to Bristol-Myers Squibb (BMS), the manufacturer of the PD-1 inhibitor.  Read more
KOL Corner
Maintenance therapy with olaparib (Lynparza) showed a 70% reduction in the risk of progression or death compared with placebo for patients with platinum-sensitive, relapsed, BRCA-mutant ovarian cancer, according to phase III SOLO2 findings reported at the 2017 Society of Gynecologic Oncology meeting. Read more
Patient Perspective
Patient-centered care is about more than you may think! Read more
Tell me something I don't know
Questions about cost-sharing subsidies, risk corridors, and what to do about red state Medicaid expansion will confront the Trump administration no matter how much the president wants to move on to other issues.  Read more